Transmission Dynamics of Carbapenemase Genes in CREC, Guangdong

Study Background and Research Question

Carbapenem-resistant Enterobacter cloacae (CREC) poses a significant threat in clinical microbiology due to its capacity for multidrug resistance and rapid dissemination in healthcare settings. The emergence of carbapenemase-encoding genes (CEGs) is a primary driver of this resistance, with the blaNDM−1 gene being especially notable for conferring widespread resistance to carbapenems and other antibiotics. The COVID-19 pandemic has further complicated the landscape, increasing antibiotic use and altering infection control dynamics. However, critical knowledge gaps have persisted regarding the molecular characteristics, prevalence, and transmission mechanisms of CEGs within CREC populations, particularly in high-incidence regions such as Guangdong Province, China. The recent reference study addresses these questions by conducting a detailed molecular epidemiological investigation across eight major teaching hospitals between December 2022 and June 2024.

Key Innovation from the Reference Study

This study distinguishes itself by systematically integrating plasmid profiling, PCR-based gene identification, conjugation experiments, and genotyping to map the diversity and transmission potential of carbapenemase genes within a defined regional and temporal context. A particular innovation lies in the dual assessment of both plasmid and chromosomal locations for CEGs, revealing complex patterns of gene carriage and transfer. The study also contextualizes these findings within the broader epidemiological shifts occurring during the COVID-19 pandemic, offering a unique lens on the interplay between public health crises and the evolution of antimicrobial resistance.

Methods and Experimental Design Insights

• Sample Collection and Typing: Fifty-four non-duplicate CREC isolates were collected from eight teaching hospitals in Guangdong province over an 18-month period. Departments and specimen types were diverse, with detailed records of patient demographics and clinical backgrounds.
• Genetic Characterization: Variable temperature Sodium Dodecyl Sulfate (SDS) plasmid elimination and PCR were employed to determine the presence and localization (chromosomal vs. plasmid) of carbapenemase genes, focusing on blaNDM−1, blaIMP, and blaKPC−2.
• Resistance Profiling: The broth microdilution method quantified antimicrobial susceptibility, comparing CEG-positive and CEG-negative groups across key antibiotics including imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
• Conjugation and Transferability: Plasmid conjugation experiments followed by PCR assessed the horizontal transfer capacity of CEGs, quantifying the success rates for blaNDM−1, blaIMP, and blaKPC−2.
• Mobile Genetic Elements: PCR identified six classes of mobile genetic elements, with ISEcp1 prevalence and combinatorial carriage patterns recorded.
• Genotyping: ERIC-PCR and NTSYS software classified isolates into 17 genotypes, providing a detailed map of CREC diversity and outbreak potential.

Protocol Parameters

• CREC isolation: Clinical isolates should be obtained from non-redundant patient samples across varied departments to capture epidemiological diversity.
• Plasmid elimination (SDS method): Employ variable temperature SDS treatments for efficient plasmid curing prior to PCR-based localization of CEGs.
• Broth microdilution: Use standardized microdilution panels to assess susceptibility to a panel of carbapenems, aminoglycosides, and fluoroquinolones.
• Conjugation assays: Conduct filter mating at 37°C, confirming transconjugants by PCR within 24-48 hours for reliable horizontal transfer rates.
• Mobile element detection: Screen for ISEcp1 and other insertion sequences using validated primer sets to map genetic mobility potential.
• Genotyping (ERIC-PCR): Profile isolates using ERIC-PCR, cluster with NTSYS to determine genotype distribution and outbreak linkage.

Core Findings and Why They Matter

The study reveals that 85.19% of CREC isolates harbored at least one carbapenemase-encoding gene, with blaNDM−1 dominating both chromosomal and plasmid contexts. Notably, 33.33% of isolates carried blaNDM−1 on both chromosomes and plasmids, while 46.30% featured it exclusively on plasmids—highlighting the plasmid's central role in gene dissemination. The presence of blaIMP and blaKPC−2, although less frequent, further diversified the resistance landscape. The study demonstrated a 95.65% success rate for CEG transfer via conjugation, underscoring the high potential for horizontal gene spread in clinical environments. Resistance rates in CEG-positive isolates were significantly elevated for key antibiotics, confirming the clinical threat posed by these strains. The identification of six mobile genetic element types, predominantly ISEcp1 (87.04% of isolates), and the observation that 40.74% carried four or more such elements simultaneously, further elucidate the molecular mechanisms underpinning gene mobility and persistence.

Epidemiologically, CEG detection was highest in male and elderly patients, within respiratory medicine departments, and in sputum samples. Genotyping revealed 17 distinct clusters, with types E and G each accounting for over 20% of isolates and spanning multiple hospitals—evidence of both clonal spread and genetic diversity.

Comparison with Existing Internal Articles

Several internal analyses provide valuable context for interpreting these findings. The article "Carbapenemase Gene Dynamics in CREC: Insights from Guangdong Study" corroborates the high prevalence and mobility of blaNDM−1 and demonstrates the urgent need for robust molecular surveillance. Additionally, "Amikacin (BAY416651): Applied Advances in Antibiotic Resistance Research" explores how the use of robust bacterial protein synthesis inhibitors, such as amikacin, supports the study of multidrug resistance in both Enterobacter cloacae and Klebsiella pneumoniae. These internal resources align with the reference study's emphasis on the importance of studying mobile genetic elements and optimizing resistance assay protocols to improve reproducibility and rigor in antibiotic resistance research.

Limitations and Transferability

The reference study's strengths lie in its comprehensive regional sampling and multi-method approach; however, limitations include the absence of whole-genome sequencing for finer resolution of resistance determinants, and its restriction to eight hospitals in Guangdong, which may limit broader generalizability. Additionally, while the study robustly demonstrates the high transferability of CEGs in vitro, clinical transfer dynamics may vary depending on patient and environmental factors. The research nonetheless offers a transferable framework for similar surveillance and resistance mechanism studies in other regions, especially those experiencing increased antibiotic use or pandemic-driven healthcare disruptions.

Research Support Resources

For experimental workflows involving resistance profiling or mechanistic studies of aminoglycoside susceptibility in CREC and related pathogens, researchers can use Amikacin (BAY416651) Aminoglycoside Antibiotic (SKU B3431). This compound, as noted in the internal protocol resource, provides a reliable bacterial protein synthesis inhibitor that is notably resistant to most aminoglycoside-modifying enzymes, supporting robust resistance research and reproducible assay development. Proper storage and preparation are essential for maintaining compound integrity in experimental setups. For detailed methods and troubleshooting of amikacin-based resistance assays, see the aforementioned protocol guides. APExBIO provides this research-grade reagent strictly for scientific use.